Skip to main content
. 2015 Jul 9;75(6):1099–1107. doi: 10.1136/annrheumdis-2014-206785

Figure 3.

Figure 3

Frequency of antibody positivity to different post-translationally modified peptides in each outcome group. Anti cyclic citrullinated peptide (CCP)-positive rheumatoid arthritis (RA) (checkered bar), anti-CCP-negative RA (vertical lines bar), persistent non-RA arthritis (black bar) and resolving arthritis (grey bar). (A) IgG reactivities: statistically significant differences in the percentages of patients with positive antibodies were observed between patients with anti-CCP-positive RA and the remaining groups for all peptides. (B) IgA reactivities: statistically significant differences in the frequency of anti-CitVimentin IgA antibody reactivities seen between patients with anti-CCP-positive RA and the remaining groups but not for the remaining post-translationally modified peptides. ***p≤0.001. (C) Distribution of the number of peptides recognised according to outcome group. The highest proportion of patients with anti-CCP-positive RA recognised three peptides while the highest proportions of patients in the remaining outcome groups did not recognise any peptides.